Coronary Artery Calcium Analysis and Reporting on Noncontrast Chest CT Scans: a Paradigm Shift in Prevention

详细信息查看全文

作者：Harvey S. Hecht
关键词：Coronary artery calcium ; Coronary artery disease ; Risk assessment ; Noncontrast CT ; Lung cancer screening ; Shared decision ; making
刊名：Current Cardiovascular Imaging Reports
出版年：2016
出版时间：March 2016
年：2016
卷：9
期：3
全文大小：3,268 KB
参考文献：1.Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med [Research Support, Non-US Gov’t. 2009;169(22):2071–7.
2.Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330–8.PubMed
3.National Coverage Analysis (NCA) for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). Available at: http://www.cms.gov/medicare-coverage-database/details/nce-details.aspx?NCAld=272&NcaName+Screening+for+Lung+Cancer+with+Low+Does+Computed+Tomography+(LDCT)&MEDCACld=68&IsPopup=y& .
4.•

Polonsky TS, Greenland P. Coronary artery calcium scores using nongated computed tomography. What to do with incidental results? Circ Cardiovasc Imaging. 2013;6:494–95. Well-reasoned editorial on the importance of reporting coronary calcium on CT scans.CrossRef PubMed
5.ACR–SCBT-MR–SPR practice parameter for the performance of thoracic computed tomography (CT) Res. 10 – 2013, Amended 2014 (Res. 39).
6.International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763–71.CrossRef
7.National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med. 2011;365:395–409.CrossRef
8.••

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: lung cancer screening. Version 1, 2013. http://www.respiratory-thessaly.gr/assets/lung_screening%201.2013.pdf . Formal recognition of CT as a screening tool for lung cancer
9.Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5_suppl):7S–37S.CrossRef PubMed
10.Wender R, Fontham ETH, Barrera E. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107–17.PubMedCentral CrossRef PubMed
11.Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144:33–8.CrossRef PubMed
12.American Lung Association. Providing guidance on lung cancer screening to patients and physicians. April 23, 2012. http://www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-guidelines/lung-cancer-screening.pdf .
13.Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.CrossRef PubMed
14.Perk J, De Backer G, Gohlke H, et al. ESC Committee for Practice Guidelines (CPG) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701.CrossRef PubMed
15.Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.11.002 .PubMedCentral
16.••

Greenland P, Alpert JS, Beller GA, American College of Cardiology Foundation; American Heart Association. 2010 ACCF ⁄ AHA guideline for assessment of cardiovascular risk in adults: a report of the American College of Cardiology Foundation ⁄ American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2010;56:e50–103. First and most evidence based guideline to strongly recommend CAC scanning.CrossRef PubMed
17.Taylor AJ, Cerqueira M, Hodgson JM. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. J Am Coll Cardiol. 2010;56:1864–94.CrossRef PubMed
18.Goff Jr DC, Lloyd-Jones DM, Bennett G. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014. doi:10.1016/j.jacc.2013.11.005 .
19.Nair A, Hansell DM. European and North American lung cancer screening experience and implications for pulmonary nodule management. Eur Radiol. 2011;21(12):2445–54.CrossRef PubMed
20.Field JK, van Klaveren R, Pedersen JH, European Randomized Screening Trial Group, et al. European randomized lung cancer screening trials: post NLST. J Surg Oncol. 2013;108:280–6.CrossRef PubMed
21.•

文摘

The quantification of coronary artery calcium (CAC) on gated noncontrast cardiac CT, as a screening test for subclinical coronary artery disease, has been consistently proven to be superior to risk factors and biomarkers for the prediction of long-term cardiovascular risk. Coronary artery calcium is also readily evaluable in every noncontrast (nongated) chest CT scan, yet there are no recommendations for reporting CAC in scans done for noncardiac indications. Lung CT scanning has been approved for lung cancer screening, and almost all the candidates are intermediate to high risk for coronary artery disease, which can be powerfully evaluated by the assessment of CAC at no additional radiation or cost. There are technical requirements for scanner detectors, slice thickness, and voltage which are easily satisfied. EKG gating provides the highest quality studies but will be more difficult to universally implement. Agatston scoring, ordinal scoring, and visual estimation of nongated scans offer alternatives and are supported by varying degrees of data. Similarly, newer reconstruction algorithms are available but are not yet widely used. Barriers to reporting include increased time and lack of increased reimbursement for CAC analysis, difficulties inherent to reporting abnormal results, and referring physician understanding and utilization of the results to alter patient education and management.